CALLIDITAS THERAPEUTICS AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 208.2 SEK | +0.10% |
|
+81.83% | +63.81% |
| May. 31 | Citigroup Downgrades Calliditas Therapeutics to Neutral From Buy, Price Target at $39 | MT |
| May. 31 | Calliditas Partner Secures European Panel Backing for Rare Kidney Disease Treatment | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 2,930 | 6,972 | 5,904 | 5,507 | 6,822 | 11,175 | - | - |
| Enterprise Value (EV) 1 | 2,177 | 5,976 | 5,162 | 4,971 | 6,815 | 11,049 | 9,969 | 7,958 |
| P/E ratio | -86 x | -14.5 x | -11.5 x | -11.9 x | -14.6 x | 37.4 x | 9.03 x | 4.38 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 15.9 x | 7,977 x | 25.7 x | 6.86 x | 5.65 x | 5.95 x | 3.49 x | 2.52 x |
| EV / Revenue | 11.8 x | 6,837 x | 22.5 x | 6.19 x | 5.65 x | 5.88 x | 3.11 x | 1.79 x |
| EV / EBITDA | -77.8 x | -15.7 x | -9.84 x | -11.8 x | -18.3 x | 98.6 x | 6.86 x | 2.91 x |
| EV / FCF | -24.4 x | -12.4 x | -11.2 x | -15.8 x | -15.2 x | 38.9 x | 7.59 x | 2.62 x |
| FCF Yield | -4.09% | -8.06% | -8.94% | -6.31% | -6.57% | 2.57% | 13.2% | 38.2% |
| Price to Book | 3.72 x | 5.18 x | 5.86 x | 6.48 x | 20.4 x | 36 x | 11.7 x | 4.03 x |
| Nbr of stocks (in thousands) | 38,708 | 49,942 | 52,342 | 59,573 | 53,672 | 53,672 | - | - |
| Reference price 2 | 75.70 | 139.6 | 112.8 | 92.45 | 127.1 | 208.2 | 208.2 | 208.2 |
| Announcement Date | 2/14/20 | 2/18/21 | 2/24/22 | 2/23/23 | 2/21/24 | - | - | - |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 184.8 | 0.874 | 229.3 | 802.9 | 1,207 | 1,879 | 3,201 | 4,434 |
| EBITDA 1 | -27.98 | -379.7 | -524.5 | -421.9 | -373.1 | 112 | 1,453 | 2,731 |
| EBIT 1 | -28.02 | -379.7 | -524.5 | -421.9 | -373.1 | 44.38 | 1,210 | 2,130 |
| Operating Margin | -15.16% | -43,446.22% | -228.67% | -52.55% | -30.91% | 2.36% | 37.81% | 48.03% |
| Earnings before Tax (EBT) 1 | -32.5 | -436.2 | -513.4 | -409.4 | -457 | -37.16 | 1,292 | 2,391 |
| Net income 1 | -32.58 | -433.5 | -500.3 | -412.3 | -466.2 | -38.29 | 1,124 | 2,024 |
| Net margin | -17.63% | -49,598.86% | -218.14% | -51.35% | -38.63% | -2.04% | 35.1% | 45.64% |
| EPS 2 | -0.8800 | -9.660 | -9.840 | -7.780 | -8.690 | 5.570 | 23.07 | 47.48 |
| Free Cash Flow 1 | -89.08 | -481.8 | -461.6 | -313.9 | -447.4 | 284.3 | 1,314 | 3,040 |
| FCF margin | -48.2% | -55,124.49% | -201.26% | -39.09% | -37.07% | 15.13% | 41.05% | 68.55% |
| FCF Conversion (EBITDA) | - | - | - | - | - | 253.75% | 90.42% | 111.31% |
| FCF Conversion (Net income) | - | - | - | - | - | - | 116.94% | 150.2% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 2/14/20 | 2/18/21 | 2/24/22 | 2/23/23 | 2/21/24 | - | - | - |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 31.2 | 49.73 | 64 | 260.1 | 429 | 191.4 | 269.4 | 294.6 | 451.6 | 295.5 | 459 | 515.8 | 603.7 | 677.6 | 751.4 |
| EBITDA 1 | -222.1 | -208.4 | -209.8 | -36.23 | 32.5 | -180.1 | -75.17 | -159.6 | 41.76 | -203.8 | -14.89 | 60.13 | 144 | - | - |
| EBIT 1 | -222.1 | -208.4 | -209.8 | -36.23 | 32.5 | -180.1 | -75.17 | -159.6 | 41.76 | -203.8 | -9.626 | 47.65 | 125.8 | - | - |
| Operating Margin | -711.86% | -418.96% | -327.88% | -13.93% | 7.57% | -94.11% | -27.91% | -54.17% | 9.25% | -68.98% | -2.1% | 9.24% | 20.85% | - | - |
| Earnings before Tax (EBT) 1 | -218.5 | -211.4 | -192.1 | -15.96 | 10.07 | -208 | -70.66 | -164.1 | -14.26 | -247.3 | -26.99 | 22.68 | 100.2 | - | - |
| Net income 1 | -219.2 | -207 | -192.4 | -9.111 | -3.681 | -187.5 | -91.93 | -168.4 | -18.37 | -246.2 | -28.55 | 20.99 | 98.2 | - | - |
| Net margin | -702.47% | -416.31% | -300.67% | -3.5% | -0.86% | -98% | -34.13% | -57.15% | -4.07% | -83.31% | -6.22% | 4.07% | 16.27% | - | - |
| EPS 2 | - | - | -3.620 | -0.1700 | -0.0700 | -3.490 | -1.710 | -3.140 | -0.3400 | -4.590 | 0.0218 | 0.7741 | 4.331 | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 2/24/22 | 5/18/22 | 8/18/22 | 11/14/22 | 2/23/23 | 5/16/23 | 8/17/23 | 11/7/23 | 2/21/24 | 5/23/24 | - | - | - | - | - |
1SEK in Million2SEK
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 754 | 996 | 742 | 536 | 7.14 | 125 | 1,205 | 3,217 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -89.1 | -482 | -462 | -314 | -447 | 284 | 1,314 | 3,040 |
| ROE (net income / shareholders' equity) | -4.63% | -43.4% | -45.1% | -46.5% | -84.7% | -24% | 112% | 86.4% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | 20.40 | 27.00 | 19.30 | 14.30 | 6.240 | 5.780 | 17.80 | 51.60 |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 18.1 | 173 | - | 2.51 | 12.8 | 31 | 44.4 | - |
| Capex / Sales | 9.78% | 19,749.08% | - | 0.31% | 1.06% | 1.65% | 1.39% | - |
| Announcement Date | 2/14/20 | 2/18/21 | 2/24/22 | 2/23/23 | 2/21/24 | - | - | - |
1SEK in Million2SEK
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
208.2
SEK
Average target price
208
SEK
Spread / Average Target
-0.10%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +63.81% | 1.06B | |
| +15.54% | 78.51B | |
| +12.05% | 9B | |
| +58.17% | 4.96B | |
| -14.94% | 4.84B | |
| -.--% | 3.72B | |
| +21.94% | 2.48B | |
| -26.63% | 2.19B | |
| +16.75% | 2.12B | |
| -37.97% | 1.94B |
- Stock Market
- Equities
- CALTX Stock
- Financials Calliditas Therapeutics AB
